Contact:

At RegeneRx:
J.J. Finkelstein
jjfnk@regenerx.com
301.280.1992

At the Financial
Relations Board:
Analyst Inquiries:
Leslie Loyet
312.640.6672

or
General Inquiries
Kathy Waller
312.640.6696

or
Media Inquiries
Tim Grace
312.640.6741

RegeneRx Biopharmaceuticals, Inc. (AMEX: RGN) (www.regenerx.com) announced that Nabila Turjman, Ph.D. has joined the company as Executive Director, Regulatory Affairs. Dr. Turjman has over sixteen years of experience in FDA regulatory affairs at a number of pharmaceutical and biotechnology firms, including Johnson & Johnson. Dr. Turjman holds a Ph.D. in Biochemistry from the American University of Beirut, Beirut, Lebanon, is fluent in three languages and has been directly involved in pharmaceutical clinical trials in the U.S. and abroad during most of her regulatory career.

"Given the rapid clinical development of our technology platform and Nabila's FDA expertise, we are very pleased that she has joined RegeneRx and look forward to utilizing her vast experience during our next stage of growth," said J.J. Finkelstein, RegeneRx's president and CEO.

About RegeneRx Biopharmaceuticals, Inc.
RegeneRx is a biopharmaceutical company developing Tß4 as a platform technology for the treatment of acute and chronic wounds and for a variety of human diseases involving tissue and organ repair under an exclusive world-wide license from the National Institutes of Health. The company holds over fifty world-wide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, including the treatment and prevention of cardiac and neurological injuries. RegeneRx previously received clearance from the U.S. FDA for its first three Phase II dermal wound healing clinical trials.

Safe Harbor Statement
The information in this press release may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the regulatory approval process and the ongoing and prospective development and commercialization of Tß4 and possible future benefits to the Company, its stockholders, and patients. Due to the nature of clinical trials, product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-KSB. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.

Back To 2005 Press Release Archives